Apollo | Sponsored by Alynlam Pharmaceuticals, Inc.

Apollo Clinical Trial
header image

Alnylam is committed to supporting the lives, health, and families of people with TTR amyloidosis (FAP) through our Alnylam Assist program.

Diagnostic testing

Alynlam Assist is our dedicated support program for patients and families affected by TTR amyloidosis (FAP). As part of this free comprehensive program, Alnylam offers third-party diagnostic testing at no cost. Testing* is available to anyone who may be experiencing symptoms of this condition, and to their relatives.

Alnylam provides diagnostic testing through an independent laboratory free of charge. Early diagnosis can help patients with TTR amyloidosis (FAP) get the help and support they need.

 

Want more information about our testing program? Connect with us >

 

*Available only in the US. Alnylam will not receive any personally identifiable patient information through this screening program.

What to expect

At Alnylam, we are working to provide support, testing, and potential new treatments for people impacted by TTR amyloidosis (FAP). Patient Connect can help patients and families stay informed about our program.

Sign up for Alnylam's Patient Connect to receive regular e-mail alerts with:

  • Information and updates on clinical studies
  • Opportunities to provide patient input
  • Educational materials

Our clinical research

At Alnylam, we strive to advance the diagnosis and treatment of TTR amyloidosis (FAP) through global clinical research. Patients with TTR amyloidosis (FAP) have limited treatment options; Alnylam is dedicated to developing, evaluating, and advancing potential new therapies.

The APOLLO trial is at the forefront of our effort. We are conducting this global clinical trial to evaluate patisiran, an investigational drug that uses the body's natural processes to lower the levels of TTR protein that cause TTR amyloidosis (FAP).